United States - English - NLM (National Library of Medicine)

atlantic biologicals corps - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate capsules are a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c calcium acetate capsules  contains calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [ ]. maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate  treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. see warnings

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c calcium acetate capsules contain calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1)] . maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium acetate on labor and delivery are unknown. a

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c: calcium acetate capsules contains calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1)] . maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium acetate on labor and delivery are unknown.

United States - English - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c calcium acetate capsules contain calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1)] . maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium acetate on labor and delivery are unknown. a

United States - English - NLM (National Library of Medicine)

state of florida doh central pharmacy - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c calcium acetate capsules contain calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1)]. maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium acetate on labor and delivery are unknown. a

United States - English - NLM (National Library of Medicine)

doh central pharmacy - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c calcium acetate capsules contain calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1)] . maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium acetate on labor and delivery are unknown. a

United States - English - NLM (National Library of Medicine)

apnar pharma - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - highlights of prescribing information these highlights do not include all the information needed to use calcium acetate capsules safely and effectively. see full prescribing information for calcium acetate capsules. calcium acetate capsules, for oral use initial u.s. approval: 1990 --------------------indications and usage--------------- - calcium acetate is a phosphate binder indicated for the reduction of serum phosphorus in patients with end stage renal disease.(1) ---------------dosage and administration----------- - starting dose is 2 capsules with each meal.(2) - titrate the dose every 2 to 3 weeks until acceptable serum phosphorus level is reached. most patients require 3 to 4 capsules with each meal.(2) ---------------dosage forms and strengths-------- - capsule: 667 mg calcium acetate capsule.(3) --------------------contraindications--------------------- - hypercalcemia.(4) ------------------warnings and precautions------------- - treat mild hypercalcemia by reducing or inter

United States - English - NLM (National Library of Medicine)

rising pharma holdings, inc. - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - highlights of prescribing information these highlights do not include all the information needed to use calcium acetate capsules safely and effectively. see full prescribing information for calcium acetate capsules. calcium acetate capsules, for oral use initial u.s. approval: 1990 --------------------indications and usage--------------- - calcium acetate is a phosphate binder indicated for the reduction of serum phosphorus in patients with end stage renal disease.(1) ---------------dosage and administration----------- - starting dose is 2 capsules with each meal.(2) - titrate the dose every 2 to 3 weeks until acceptable serum phosphorus level is reached. most patients require 3 to 4 capsules with each meal.(2) ---------------dosage forms and strengths-------- - capsule: 667 mg calcium acetate capsule.(3) --------------------contraindications--------------------- - hypercalcemia.(4) ------------------warnings and precautions------------- - treat mild hypercalcemia by reducing or interruptin

United States - English - NLM (National Library of Medicine)

carilion materials management - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - eliphos® is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c eliphos® contains calcium acetate. animal reproduction studies have not been conducted with calcium acetate tablets, and there are no adequate and well controlled studies of calcium acetate tablets use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1)] . maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. eliphos® treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of eliphos® on labor and delivery are unknown. eliphos® contain

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - phoslo is indicated for the control of hyperphosphatemia in end stage renal failure and does not promote aluminum absorption. patients with hypercalcemia.